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Introduction MOL #65169 5 apoptosis (Senese et al., 2007; Weichert et al., 2008) . Class II HDACs appear not to regulate cell proliferation and are primarily involved in cellular development and differentiation (Verdin et al., 2003) . In addition, MS-275, a reported class I HDAC-specific inhibitor, triggers effects reminiscent of those achieved by pan-isoform HDACi, including cell-cycle effects, p21
Waf1 up-regulation and initiation of apoptosis.
The cell autonomous anti-proliferative activity of HDACi results from a combination of inhibiting cell cycle progression and promoting cell death (Bernhard et al., 2001; Peart et al., 2003) . However, HDACi can also promote cell death in arrested cells although the drugs require a longer exposure to achieve the same effects (Burgess et al., 2004) . HDACi produce a number of cell cycle effects including G1/S phase arrest which is correlated with increased p21 Waf1 expression and is observed in a wide range of cell lines with all HDACi reported to date (Archer et al., 1998; Burgess et al., 2001 ); a G2 phase checkpoint arrest observed mainly in normal non-transformed cell lines (Qiu et al., 2000) ; and mitotic defects including mitotic arrest and mitotic slippage also observed in most cell lines in response to a broad range of HDACis (Stevens et al., 2008; Warrener et al., 2003) . The HDACi sensitive G2 phase checkpoint appears to be the basis for the tumour selective cytotoxicity of these drugs with the majority of tumour cell lines being sensitive due to their defective checkpoint whereas normal tissues are protected by their intact G2 phase checkpoint response (Krauer et al., 2004; Qiu et al., 2000; Warrener et al., 2003) . Progression through the HDACi induced aberrant mitosis induces rapid cell death (Blagosklonny et al., 2002; Dowling et al., 2005; Warrener et al., 2003) , and this appears to be a significant contributor to the cytotoxicity of these drugs.
The cell cycle effects of HDACi significantly contribute to the selective cytotoxicity of these drugs. Here we have investigated the cell cycle effects of a novel class I specific histone deacetylase inhibitor MGCD0103 (Fournel et al., 2008) , and compared it with an This article has not been copyedited and formatted. The final version may differ from this version. promotes tumour cell-selective cytotoxicity. It also triggered mitotic failure, characterized by a delay in mitosis and subsequent mitotic slippage. However, in contrast to SBHA treatment, there was no p21 Waf1 induction until at least 12h after MGCD0103 treatment or G1 phase arrest, which contributes to the increased cytotoxicity of this drug. MGCD0103 also possesses a novel activity, it destabilises microtubules in both interphase and mitosis, and this activity underlies the improved cytotoxicity of this drug.
Materials and Methods

Materials
MGCD0103 and 001 (inactive analogue of MGCD0103) were kindly provided by MethylGene Inc (Montreal Canada). Suberic bishydroxamic acid (SBHA) was purchased from Sigma Aldrich. All compounds were dissolved in dimethyl sulphoxide (DMSO) with MGCD0103 and 001 dissolved as 10mM stock solutions and SBHA dissolved as 500 mM solution.
Cell culture, synchrony and drug treatment HDACi were added to either asynchronous cells or cells synchronized by simple thymidine block (2 mM for 17 h) in early S phase or late G2 phase (7 h release from thymidine), and harvested at the indicated time points. For early S phase addition, HDACi were added immediately after release, whereas for G2 phase addition, HDACi were added 7 h after release. For the mitotic shake-off experiments, HDACi were added in early S phase and 0.25µg/ml nocodazole was added 7 h after release. Mitotic cells were collected by mechanical shake-off 3h later. In parallel experiments, HDACi were added in combination with the microtubule-disrupting agents taxol (100 nM) or nocodazole (0.25 µg/ml) to asynchronous cell populations for 24 h. p21 Waf1 knockdown was achieved by transfection with 5nM p21 anti-sense oligonucleotides (Ambion and Dharmacon Smart Pool) using Lipofectamine LF2000 transfection reagent (Invitrogen), according to the manufacturer's recommendations. Silencer ® Select Negative Control siRNA #1 (Ambion) was used as scrambled siRNA.
Flow cytometry
For flow cytometric analysis, both floating and attached cells were harvested. Cells were fixed in ice cold 70% ethanol and then stained with 4µg/ml propidium iodide (Sigma) and 400 µg/ml RNase A (Invitrogen) in PBS. The stained cells were subsequently filtered through a 37 µm gauze and analyzed on a FACSCailbur (BD Biosciences) using CellQuestPro ® (BD Biosciences). The different subpopulations were quantified using ModFit LT ® program (Verity Software House Inc). Experiments were performed in triplicate and the presented as mean and standard deviation. P values were calculated by 2 tailed T-test.
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Results
MGCD0103 induces delay increase in p21 Waf1 and fails to G1 phase arrest
The effects of MGCD0103 on the cell cycle and on cell killing were compared with the representative pan HDAC inhibitor SBHA, which we have previously demonstrated to have similar cell cycle effects as other HDACi including SAHA (suberoylanilide hydroxamic acid), TSA (trichostatin A) and sodium butyrate (Stevens et al., 2008; Warrener et al., 2003) .
The potency of MGCD0103 and SBHA in promoting histone acetylation and apoptosis was determined using the level of histone H3 Lys9 acetylation and caspase 3 and 7 activation, respectively. MGCD0103 at 10 M and SBHA at 500 M produced maximal H3 Lys9 acetylation and activated caspase 3/7 to a similar extent ( Figure 1A and B) and were used as equipotent doses throughout this work. These doses of the drugs also induced H3 Lys 9 acetylation with very similar kinetics, although only SBHA increased -tubulin acetylation indicating that it also inhibited the class II HDAC6 ( Figure 1C ).
This article has not been copyedited and formatted. The final version may differ from this version. Using the equipotent concentrations of MGCD0103 (10 M) and SBHA (500 M) which induced maximal histone acetylation ( Figure 1A) , the effects on cell cycle were analysed. MGCD0103 produced two immediately noticeable differences from SBHA treatment. There was a striking accumulation of cells with 4n DNA content from 6 h posttreatment which continued to increase to 24 h in the MGCD0103 treated cells, whereas in the SBHA treated cells there was a loss of the S phase population and accumulation of cells in G1 phase (Figure 2A and B). Analysis of cell cycle proteins reported to be regulated by
HDACi treatment revealed striking difference between the effects of MGCD0103 and SBHA.
Surprisingly, MGCD0103 did not increase p21 Waf1 expression until 24 h treatment, whereas all HDACi, exemplified by SBHA rapidly induced its expression ( Figure 2C ). There was also a lack of both increased cyclin E expression and down regulation of cyclin A that are normally associated with HDACi treatment (as observed with SBHA, Figure 2C ). The marked accumulation of phosphorylated B23 (pB23), a marker of mitosis, at 6 and 12 h posttreatment only in the MGCD0103 treated cells ( Figure 2C ), indicated that the 4n DNA peak observed corresponded to cells accumulating in mitosis at 6 and 12 h after MGCD0103 treatment ( Figure 2A ). Interestingly, the 4 n peak persisted to 24 h whereas the pB23 signal was lost at this time. Both HDACi also induced PARP cleavage, a marker of caspase 3/7 activation and apoptosis, to a similar extent at 24 h although only the MGCD0103 treated cells had a readily detectible sub diploid population at 24 h. An inactive analog of MGCD0103, 001, had no effect on either histone H3 or -tubulin acetylation. These effects of MGCD0103 on both p21 Waf1 expression and accumulation in mitosis compared with SBHA were also observed in four other cell lines tested (Supplementary Figure S1 and data not shown).
The loss of the S phase population and G1 phase arrest observed with the majority of
HDACi including SBHA, was demonstrated to be a consequence of HDACi induced p21
Waf1
MGCD0103 induces mitotic defects and mitotic slippage
To examine the effects of drug treatment on entry into and progression through mitosis without the complication of cell death, HeLa cells over expressing Bcl-2 (HeLa-Bcl2) that are relatively refractory to HDACi-induced apoptosis were used (Supplementary Figure S2; ( Warrener et al., 2003) ). When MGCD0103 was added to thymidine block release synchronised HeLa-Bcl2 cells and followed using time lapse microscopy, it delayed entry into mitosis by < 2 h, a little longer than SBHA treatment (Supplementary Figure S3) . Figure S4) . Thus, MGCD0103 does initiate a mitotic checkpoint arrest but prematurely exits, similar to other HDACi, although it disrupts the normal mitotic spindle formation in a manner unique to this drug.
Interestingly, the effect on cytokinesis was another feature that discriminated between Figure 4D ). In contrast, SBHA does not affect mitosis when added in G2 phase (Warrener et al., 2003) . The presence of this very high proportion of failed cytokinesis accounts for the 4n population with no pB23 24 h after MGCD0103 treatment.
MGCD0103 induces a G2 phase arrest in normal cells
The mitotic effects described above were previously only observed in HDACi treated tumour and immortalised cell lines which had a defect in an HDACi sensitive G2 phase checkpoint.
Normal cells competent for the checkpoint were relatively insensitive to HDACi induced cytotoxicity (Qiu et al., 2000) . To determine whether MGCD0103 triggered the G2 checkpoint in normal cells, asynchronous cultures of primary neonatal foreskin fibroblasts Figure 5A ) and SBHA (data not shown) treatment as early as 8 h after treatment. Time lapse microscopy also revealed a block of entry into mitosis 6 h after drug treatment ( Figure 5B ). This indicated that the drugs were required to be present throughout S phase for the G2 arrest to be initiated. MGCD0103 treatment did not induce significant cell death in NFF cultures over the time course of these experiments, similar to the lack of cytotoxicity observed with SBHA and other pan HDACi treatment.
MGCD0103 disrupts microtubule stability
The surprising observations that MGCD0103 treatment disrupted mitotic spindle assembly, Figure S5) . The effect of MGCD0103 on microtubules appears to be either destabilising microtubules or blocking polymerisation. To examine this, the effect of MGCD0103 treatment on taxol induced microtubule polymerisation and bundling was examined. Taxol induced microtubule bundling was unaffected by MGCD0103 treatment, indicating that it was not affecting taxol binding to -tubulin and stabilising microtubules ( Figure 6D ).
The ability of HDACi to induce mitotic slippage would suggest that they should combine with microtubule disrupting agents to promote cell death. This was observed with combination of SBHA with both nocodazole and taxol, where the increase in the sub diploid population for each combination exceeded the additive effects of the individual drugs by 2.5 to 3 fold, with each combination (SBHA + nocodazole or taxol) producing a similar degree of synergy ( Figure 7 ). Although the combinations with MGCD0103 produced the higher levels of cell death, the effect of combination with nocodazole was little more than additive, producing a 50% increase in the sub diploid population over the additive effect. This combination produced the same level of sub diploid cells as the SBHA combinations ( Figure   7B ). By contrast, the combination of MGCD0103 with taxol had a 2 fold increase in the sub diploid population relative to the additive effect of the individual drug when used alone. This effect is similar to the degree of apparent synergy obtained with SBHA and both microtubule drugs ( Figure 6B ). The relatively weak effect of the microtubule destabilising drug nocodazole in combination with MGCD0103 compared to the effect with the stabilising drug taxol, provides evidence that some of the increased cytotoxicity of MGCD0103 is likely to be based on the combination of HDACi and microtubule destabilising activities of the drug. The A: Synchronised HeLa cells were treated in either early S phase with 500 M SBHA or 10 M MGCD0103, or an equal volume of DMSO as a control (Con), with and without addition of nocodazole (Noco) 7 h after release from the synchrony arrest as they progressed through G2 phase into mitosis. Cells were followed by time lapse microscopy and the time cells stayed in mitosis was measured. In each case >100 cells were analysed. . 0 M MGCD0103 was also added at 7 h after release from the synchrony arrest when they had entered G2 phase (G2 MGCD). Asynchronously growing NFF cultures were treated with either 500 M SBHA, 10 M MGCD0103 or equal volume of DMSO as control (Con), and A, analysed by FACS at the indicated times or B, followed by time lapse microscopy. Cells were scored for entry into mitosis and the cumulative score is shown. Over 100 cells were analysed for each treatment. 
